Why M&A is back; AI regulations lacking; quantum sensing investment, and more: Pharma Pulse for February 23, 2024
The latest news for pharma industry insiders.
© vectorfusionart - stock.adobe.com
Pharma Pulse rounds up insights every weekday morning from across health care. Here is the February 23, 2024 edition:
From PharmExec’s interview with Arthur Wong, managing director of S&P Global Ratings, on the state of the M&A market: “Last year, pharma companies basically stopped M&A, so the big trend right now is the return of M&A. This underscores how important it has become for the industry, especially for companies looking to hit their target growth in the future.”
Regulators say they need help monitoring AI tech in health care
As reported by Ruth Reader in Politico: “Doctors are already using unregulated artificial intelligence tools such as note-taking virtual assistants and predictive software that helps them diagnose and treat diseases. Government has slow-walked regulation of the fast-moving technology because the funding and staffing challenges facing agencies like the Food and Drug Administration in writing and enforcing rules are so vast. It’s unlikely they will catch up any time soon.”
Novo Nordisk invests in ‘quantum sensing’ for disease diagnosis, prevention
From their news release: “Quantum sensing holds the potential to reform biomedical and health sciences by improving the diagnosis and prevention of diseases. The Novo Nordisk Foundation has awarded a grant of DKK 150 million to establish the Copenhagen Center for Biomedical Quantum Sensing, under which an international research collaboration aims to develop novel quantum sensing principles and techniques for early detection of diseases.”
Are digital health interventions a hypertension equalizer?
From the American Journal of Managed Care: Patients from disadvantaged populations who underwent digital health interventions for management of hypertension experienced significant reductions in blood pressure (BP), according to a new study.
From National Institutes of Health (@NIH) on X: “News: Scientists develop a simple blood test to quickly diagnose sarcoidosis.”
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs.
An Exploration of Compounding Practices
May 22nd 2025In a Q&A with Pharma Commerce, Kurt Lunkwitz, ProRx Pharma’s COO, uncovers the stringent requirements that 503B outsourcing facilities must abide by under the Drug Quality and Security Act, while also shedding light on the FDA’s impact when it comes to improving the safety, quality, and trust in compounded drugs.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
